Coherus BioSciences, Inc.

NasdaqGM:CHRS Stock Report

Market Cap: US$170.5m

Coherus BioSciences Management

Management criteria checks 3/4

Coherus BioSciences' CEO is Denny Lanfear, appointed in Sep 2010, has a tenure of 14.25 years. total yearly compensation is $5.90M, comprised of 16.7% salary and 83.3% bonuses, including company stock and options. directly owns 0.99% of the company’s shares, worth $1.69M. The average tenure of the management team and the board of directors is 2.8 years and 3.4 years respectively.

Key information

Denny Lanfear

Chief executive officer

US$5.9m

Total compensation

CEO salary percentage16.7%
CEO tenure14.3yrs
CEO ownership1.0%
Management average tenure2.8yrs
Board average tenure3.4yrs

Recent management updates

Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

May 23
Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

Recent updates

Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development

Dec 16

Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%

Nov 06
Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive

Sep 22
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

Aug 13

Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S

Aug 07
Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

May 31

Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

May 23
Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Mar 21

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Feb 03
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Coherus BioSciences: FDA Approvals Spice Up The Pipeline

Jan 17

Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

Dec 20
Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

May 13
The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3

Sep 19

Coherus: 2022 Is In Many Ways A Make Or Break Year

Aug 24

Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli

Aug 03

Coherus, Shanghai Junshi refiling for toripalimab gets FDA review in rare head/neck cancer

Jul 06

CEO Compensation Analysis

How has Denny Lanfear's remuneration changed compared to Coherus BioSciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$450k

Jun 30 2024n/an/a

-US$29m

Mar 31 2024n/an/a

-US$59m

Dec 31 2023US$6mUS$983k

-US$238m

Sep 30 2023n/an/a

-US$217m

Jun 30 2023n/an/a

-US$264m

Mar 31 2023n/an/a

-US$271m

Dec 31 2022US$7mUS$945k

-US$292m

Sep 30 2022n/an/a

-US$279m

Jun 30 2022n/an/a

-US$230m

Mar 31 2022n/an/a

-US$210m

Dec 31 2021US$9mUS$885k

-US$287m

Sep 30 2021n/an/a

-US$232m

Jun 30 2021n/an/a

-US$165m

Mar 31 2021n/an/a

-US$76m

Dec 31 2020US$7mUS$857k

US$132m

Sep 30 2020n/an/a

US$162m

Jun 30 2020n/an/a

US$181m

Mar 31 2020n/an/a

US$145m

Dec 31 2019US$5mUS$751k

US$90m

Sep 30 2019n/an/a

-US$12m

Jun 30 2019n/an/a

-US$118m

Mar 31 2019n/an/a

-US$185m

Dec 31 2018US$4mUS$702k

-US$209m

Sep 30 2018n/an/a

-US$196m

Jun 30 2018n/an/a

-US$196m

Mar 31 2018n/an/a

-US$208m

Dec 31 2017US$3mUS$656k

-US$238m

Compensation vs Market: Denny's total compensation ($USD5.90M) is above average for companies of similar size in the US market ($USD1.44M).

Compensation vs Earnings: Denny's compensation has been consistent with company performance over the past year.

CEO

Denny Lanfear (69 yo)

14.3yrs

Tenure

US$5,897,924

Compensation

Mr. Dennis M. Lanfear, also known as Denny, Co-founder, Chairman, Chief Executive Officer and President of Coherus Biosciences Inc. since September 2010. Mr. Lanfear serves as the President of Lanfear Capi...

Leadership Team

NamePositionTenureCompensationOwnership
Dennis Lanfear
Chairman14.3yrsUS$5.90m0.99%
$ 1.7m
Bryan McMichael
Former Interim CFO2.3yrsUS$1.07m0.023%
$ 39.0k
Paul Reider
Chief Commercial Officer3.9yrsUS$1.93m0.077%
$ 132.0k
Richard Hameister
Chief Technical Officer2.9yrsno datano data
Jodi Sievers
Vice President of Investor Relations & Corporate Communicationsno datano datano data
Andy Rittenberg
Executive Vice President of General Counselless than a yearno datano data
Scott Saywell
Executive Vice President of Corporate Development1.9yrsno datano data
Rebecca Sunshine
Chief Human Resources Officerno datano datano data
Michael Chen
Senior Vice President of Commercial Analytics & Tradeno datano datano data
Theresa Lavallee
Chief Development Officer & Chairman of Scientific Advisory Board2.9yrsno datano data
Rosh Dias
Chief Medical Officer2.8yrsno datano data

2.8yrs

Average Tenure

56.5yo

Average Age

Experienced Management: CHRS's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Dennis Lanfear
Chairman14.3yrsUS$5.90m0.99%
$ 1.7m
Theresa Lavallee
Chief Development Officer & Chairman of Scientific Advisory Board2.9yrsno datano data
Mats Wahlstrom
Lead Independent Director12.9yrsUS$228.69k0.087%
$ 148.0k
Mark Stolper
Independent Director3.9yrsUS$198.69k0.0076%
$ 13.0k
Ali Satvat
Independent Director10.6yrsUS$65.00k0%
$ 0
Lee Newcomer
Independent Director2.8yrsUS$186.19k0%
$ 0
James Daly
Member of Strategic Advisory Board1.3yrsno datano data
Charles Newton
Independent Director2.6yrsUS$188.69k0%
$ 0
Jill O'Donnell-Tormey
Independent Director2.6yrsUS$183.69k0%
$ 0
Kimberly Tzoumakas
Independent Director4.4yrsUS$193.69k0%
$ 0
Carl Ware
Member of Scientific Advisory Board3.4yrsno datano data
Thomas Graeber
Member of Scientific Advisory Board3.4yrsno datano data

3.4yrs

Average Tenure

60yo

Average Age

Experienced Board: CHRS's board of directors are considered experienced (3.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 00:01
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Coherus BioSciences, Inc. is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Balaji PrasadBarclays
Balaji PrasadBarclays